Abstract
It has long been suggested that, in humans, the biosynthesis of salsolinol (Sal), a dopamine (DA)-derived isoquinoline alkaloid, might occur by condensation of DA with acetaldehyde or with pyruvic acid followed by oxidative decarboxylation and reduction (Figure 1). Sal possesses an asymmetric center at C-1 and exists as R and S enantiomers. There is supportive evidence that, at least in healthy subjects under physiological conditions, Sal biosynthesis should result from the condensation of DA with pyruvic acid: 1) 1-carboxysalsolinol and 1,2-dehydrosalsolinol (DSal) have been detected in human brain and urine together with Sal (Sjöquist and Ljungquist, 1985; Ung-Chhun et al., 1985; Dostert et al., 1990a); and 2) the presence of only the R enantiomer of Sal in urine of healthy subjects (Dostert et al., 1991) would not be consistent with this compound arising from the non-enzymic condensation of DA with acetaldehyde.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bieck, P.R., Antonin, K.-H., Farger, G., Nilsson, E.B., Schmidt, F,.K., Dostert, P., Strolin Benedetti, M., and Waldmeier, P.C., 1993, Clinical pharmacology of the new COMT inhibitor CGP 28 014, Neurochern. Res. 18: 1163.
Dordain, G., Dostert, P., Strolin Benedetti, M., and Rovei, V., 1984, Tetrahydroisoquinoline derivatives and parkinsonism, in: “Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors,” Tipton, K.F., Dostert, P. and Benedetti, M. Strolin, eds., Academic Press, London.
Dostert, P., Strolin Benedetti, M., Bellotti, V., Allievi, C., and Dordain, G., 1990a, Biosynthesis of salsolinol, a tetrahydroisoquinoline alkaloid, in healthy subjects, J. Neural Transm. [GenSect] 81: 215.
Dostert, P., Strolin Benedetti, M., Bellotti, V., Dordain, G., Vernay, D., and Deffond, D., 1990b, Urinary excretion of salsolinol enantiomers and 1,2-dehydrosalsolinol in patients with degenerative dementia, in: “Alzheimer’s Disease. Epidemiology, Neuropathology, Neurochemistry, and Clinics (Key Topics in Brain Research),” Maurer, K., Riederer, P. and Beckmann, H., eds., Springer-Verlag, Germany.
Dostert, P., Strolin Benedetti, M., Dordain, G., and Vernay, D., 1991, Urinary elimination of salsolinol enantiomers in alcoholics, J. Neural Transm. [GenSect] 85: 51.
Dostert, P., Strolin Benedetti, M., Della Vedova, F., Allievi, C., La Croix, R., Dordain, G., Vemay, D., and Durif, F., 1993, Dopamine-derived tetrahydroisoquinolines and Parkinson’s disease, in: “Advances in Neurology,” Narahayashi, H., Nagatsu, T., Yanagisawa, N. and Mizuno, Y., eds., Raven Press Ltd., New York.
Elsworth, J.D., Glover, V., Reynolds, G.P., Sandler, M., Lees, A.J., Phuapradit, P., Shaw, K.M., Stem, G.M., and Kumar, P., 1978, Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the “cheese effect”, Psychopharmacology 57: 33.
Knoll, J., 1992, The pharmacological profile of (-)deprenyl (selegiline) and its relevance for humans: a personal view, Pharmacol. Toxicol. 70: 317.
Lee, D.H., Mandoza, M., Dvorozniak, M.T., Chung, E., van Woert, M.H., and Yahr, M.D., 1989, Platelet monoamine oxidase in Parkinson patients: effect of L-deprenyl therapy, J. Neural Transm. [PDSect] 1: 189.
Naoi, M., Dostert, P., Yoshida, M., and Nagatsu, T., 1993, N-methylated tetrahydroisoquinolines as dopaminergic neurotoxins, Adv. Neurol. 60: 212
Niwa, T., Takeda, N., Yoshizumi, H., Tatematsu, A., Yoshida, M., Dostert, P., Naoi, M., and Nagatsu, T., 1991, Presence of 2-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline,novel endogenous amines, in parkinsonian and normal human brains, Biochem. Biophys. Res. Commun. 177: 603.
Sjóquist, B., and Ljungquist, C., 1985, Identification and quantification of 1-carboxysalsolinol and salsolinol in biological samples by gas chromatography-mass spectrometry, J. Chromatogr. Biomed. Appl. 343: 1.
Thornton, C., Doré, C.J. Elsworth, J.D., Herbert, M., and Stern, G.M., 1980, The effect of deprenyl, a selective monoamine oxidase B inhibitor, on sleep and mood in man, Psychopharmacology 70: 163.
Ung-Chhun, N., Cheng, B.Y., Pronger, D.A., Serrano, P., Chavez, B., Fernandez Perrez, R., Morales, J., and Collins, M.A., 1985, Alkaloid adducts in human brain: coexistence of 1-carboxylated and noncarboxylated isoquinolines and ß-carbolines in alcoholics and nonalcoholics, Prog. Clin. Biol. Res. Gggg 183: 125.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this chapter
Cite this chapter
Dostert, P., Deffond, D., Croix, R.L., Vernay, D., Benedetti, M.S., Dordain, G. (1995). Effect of Selegiline Administration on the Urinary Excretion of Dopamine-Derived Tetrahydroisoquinoline Alkaloids in Parkinson’s Disease Patients. In: Hanin, I., Yoshida, M., Fisher, A. (eds) Alzheimer’s and Parkinson’s Diseases. Advances in Behavioral Biology, vol 44. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9145-7_81
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9145-7_81
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-9147-1
Online ISBN: 978-1-4757-9145-7
eBook Packages: Springer Book Archive